Protalix BioTherapeutics

PLXNYSE Israel Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$225.601 M

$2.80 -1.41%

Close of 23 Sept 2026

Revenue

$52.7M

#2715 by revenue

Earnings

-$6.60M

Loss-making

Shares outstanding

80,571,642

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#88Sutro BiopharmaSTRO$260.8M
#89Lineage Cell TherapeuticsLCTX$242.0M
#90Protalix BioTherapeuticsPLX$225.6M
#91AlectorALEC$225.5M
#92CompugenCGEN$221.3M

What if Protalix BioTherapeutics were worth as much as…

Open the what-if tool →

Gold $29.8T

$370,439.60

Per share 132,300× higher

Bitcoin $1.69T

$21,026.26

Per share 7,509× higher

Nvidia $5.43T

$67,452.90

Per share 24,090× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Protalix BioTherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.